Eradication of factor viii inhibitors in patients with mild and moderate hemophilia A

Authors


  • Conflict of interest: C.K. receives research support from Novo Nordisk, Inc, has been a consultant for Inspiration Biopharmaceuticals and has participated in an advisory board for Baxter Biopharmaceuticals. All other authors have no conflict of interest.

Ancillary